The Wolf Administration is working to reduce over-prescribing of opioids through use of the the Prescription Drug Monitoring Program and prescribing guidelines.

This page describes information on the impacts of opioids on families and children.

View quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level.
Please see Overdose Data Technical Notes for additional details: : https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

View trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level.
Please see Overdose Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/OverdoseDataTechnicalNotes.pdf

Estimated Accidental and Undetermined Drug Overdose Deaths 2012-2018 and provisional estimates of annual counts of deaths for 2019 generated from preliminary 2019 mortality data as of February 2020.
NOTE: Finalized death certificates for overdose deaths are often delayed by 3-6 months. Counties labeled “no value” have data suppressed due to counts between 1 and 9.
Dataset includes overdose deaths where the Manner of Death is Accidental or Undetermined.
Overdose Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Accidental and Undetermined drug overdose deaths are identified using underlying cause-of-death codes X40–X44, and Y10–Y14, and include
- R99 when the Injury Description indicates an overdose death.
- X49 when literal COD is Mixed or Combined or Multiple Substance Toxicity, as these are likely drug overdoses
- X47 when substance indicated is difluoroethane, alone or in combination with other drugs
Source Pennsylvania Prescription Drug Monitoring Program *
* These data were supplied by the Bureau of Health Statistics and Registries, Harrisburg, Pennsylvania. The Bureau of Health Statistics and Registries specifically disclaims responsibility for any analyses, interpretations or conclusions.
- Estimates are broken down by type of drugs involved in the overdose
- Any Drug Overdose Death - all drug overdose deaths, regardless of type of drug involved, excluding alcohol only deaths
- Opioid Overdose Death - any overdose death involving opioids, prescription or illegal

This dataset reports number of successful naloxone reversals by police officers, as self-reported by municipal police departments, Capitol Police, and Pennsylvania State police. The data is stratified by county and by year. Note that there is no legislation mandating that law enforcement report naloxone reversals to DDAP; these data represent voluntary self-reports from departments.
NA - Not applicable. No FIPS code or county code exist for Pennsylvania State Police and Capitol Police. Also, counties labelled “NA” do not have municipal police departments and are only covered by Pennsylvania State Police.

This page is part of the community impacts section and describes impacts on the economic cost of the opioid crisis by estimating lost wages.

This dataset reports number of successful naloxone reversals by police officers, as self-reported by municipal police departments, Capitol Police, and Pennsylvania State police. The data is stratified by county and by year. Note that there is no legislation mandating that law enforcement report naloxone reversals to DDAP; these data represent voluntary self-reports from departments.
NA - Not applicable. No FIPS code or county code exist for Pennsylvania State Police and Capitol Police. Also, counties labelled “NA” do not have municipal police departments and are only covered by Pennsylvania State Police.

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

This dataset reports the name, street address, city, county, zip code, telephone number, latitude, and longitude of Pennsylvania Department of Drug and Alcohol Programs (DDAP) drug and alcohol treatment facilities in Pennsylvania as of May 2018.

The primary difference between the three types of treatment facilities is their funding. Centers of Excellence (COEs) were grant funded by the Department of Human Services, PacMATs were grant funded by the Department of Health, and all other facilities are funded by either billing insurance or billing the county in the case of uninsured clients.

Programmatically, COEs differ from the other types because they are designed to serve as “health homes” for individuals with Opioid Use Disorder (OUD). This means that the care coordination staff at the COE is charged with coordinating all kinds of health care (physical and behavioral health) as well as recovery support services. They do this by developing hub-and-spoke networks with other healthcare providers and other sources for recovery supports, such as housing, transportation, education and training, etc. All COEs are required to accept Medicaid.

PacMATs also operate in a hub-and-spoke model, but it is different from COEs. PacMATs endeavor to coordinate the provision of Medication Assisted Treatment (MAT) by identifying a core hub of physicians in a health system that work with other providers in the health system (spokes) to train them about the safe and effective provision of MAT so that there are more providers in a health system that are able to confidently prescribe various forms of MAT. I do not know whether all PacMATs are required to accept Medicaid as a term of their receipt of the grant, but I do know that all currently designated PacMATs are health systems that do accept Medicaid. PacMAT services have been advertised as being available to all people regardless of insurance type, so I assume this means they are required to serve Medicaid clients, commercially insured clients, and uninsured clients. In the PacMAT program the Hub is supported right now by grant funding (in the future funding such as a per patient/per month capitated rate) and the spokes bill insurance (both Medicaid and Commercial)

DDAP facilities may also be designated as COEs and/or PacMATs. If they are, it means they applied for a specific grant fund and have committed to carrying out the activities of the grant described above. To be clear, DDAP does not run any treatment facilities; they license them. These can be MAT providers such as methadone clinics, providers of outpatient levels of care (i.e., more traditional drug and alcohol counseling services) or inpatient levels of care, such as residential rehabilitation programs. Every facility is different in terms of the menu of services it provides. Every facility also gets to decide what forms of payment they will accept. Many accept Medicaid, but not all do. Some only accept private commercial insurance. Some accept payment from the county on behalf of uninsured clients. And some charge their clients cash for services.